Emerg Infect Dis by Kusumoto, Masahiro et al.
panel A, http://wwwnc.cdc.gov/EID/article/22/7/16-0179-
Techapp1.pdf). The chimeric nature of the virus strain was 
confirmed by RT-PCR with primers spanning possible re-
combination sites and analysis of overlapping reads from 
next-generation sequencing.
Annotation of the sequence of SeCoV/GER/
L00930/2012 performed on the basis of SeCoV/ 
Italy/213306/2009 identified a similar putative coding 
sequence with a TGEV backbone and a spike coding se-
quence similar to that for PEDV (online Technical Ap-
pendix panel B). Downstream of the spike protein–coding 
open reading frame (ORF), an additional hypothetical ORF 
was identified in both SeCoV sequences. The coded amino 
acid sequences (27 aa in the virus from Germany and 30 aa 
in the virus from Italy) resembled an N- and C-terminally 
truncated TGEV nonstructural protein 3a. The difference of 
3 aa between the 2 strains is the result of a 10-bp deletion at 
the 3′-end of the hypothetical ORF, which shifted the stop 
3 codons to the 5′- end (online Technical Appendix Figure, 
panel B) in SeCoV/GER/L00930/2012. This deletion is ap-
parently located within the potential 3′ recombination site 
(online Technical Appendix Figure, panel B).
It is tempting to speculate that SeCoV/Ita-
ly/213306/2009 is a precursor of SeCoV/GER/L00930/ 
2012, and that other members of this novel genotype are 
still undetected. These viruses might be targets of second-
ary mutation and recombination events. Therefore, more 
chimeric CoVs should be identified to determine the poten-
tial origin of the recombination event.
In conclusion, we detected an enteric CoV that resem-
bled the TGEV/PEDV chimeric virus reported by Boniotti 
et al. (1). Although these findings support the notion that 
CoV genomes are subject to mutations and recombination 
events, problems in disease diagnosis can be foreseen. In 
countries where porcine epidemic diarrhea, transmissible 
gastroenteritis, or both of these diseases are reportable, 
correct diagnosis and reporting might be difficult. Thus, 
diagnosticians should be aware of possible recombinants 
of swine CoVs. Diagnostic problems can be prevented by 
use of a double-check strategy with techniques specific for 
different genome regions. Apart from diagnostic obstacles, 
the effect of virus recombinations in terms of virulence and 
organ tropism is unknown and needs further investigations.
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To the Editor: Colistin is an old-generation antimicro-
bial agent; however, because it is one of the few agents that 
remain effective against multidrug-resistant gram-negative 
bacteria (e.g., carbapenem-resistant Pseudomonas aeru-
ginosa and Enterobacteriaceae), its clinical usefulness is 
being increasingly recognized (1). Previous reports have 
described the mechanisms of colistin resistance (2) as be-
ing chromosomally mediated and not associated with hori-
zontal gene transfer. However, from 2011 through 2014, 
a plasmid-encoded colistin-resistance gene, mcr-1, was 
identified in colistin-resistant Escherichia coli isolated in 
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Figure. Electron micrograph of a new chimeric swine enteric 
coronavirus (SeCoV/GER/L00930/2012), Germany, 2012. Scale 
bar indicates 100 nm.
China, particularly from animals. Specifically, mcr-1–posi-
tive isolates were found in 21% of healthy swine at slaugh-
ter, 15% of marketed pork and chicken meat, and 1% of 
hospitalized human patients (3). A study of E. coli isolated 
from healthy cattle, swine, and chickens in Japan during 
2000–2014 found only 2 (0.02%) of 9,308 isolates posi-
tive for mcr-1 (4). We report the rates at which mcr-1 was 
detected in our stored collection of E. coli isolates from 
diseased swine (swine with diarrhea or edema disease), 
hereafter referred to as swine-pathogenic E. coli.
We recently analyzed swine-pathogenic E. coli strains 
isolated from diseased swine throughout Japan during 
1991–2014 (5). We analyzed all swine disease-associated 
E. coli strains isolated from the 23 Livestock Hygiene Ser-
vice Centers in Japan (including prefectures that covered 
75% of total swine production in Japan in 2014) and sent 
to the National Institute of Animal Health for diagnostic 
purposes during 1991–2014. Among the 967 strains exam-
ined, 684 (71%) belonged to E. coli serogroup O139, O149, 
O116, or OSB9. 
In the study reported here, we investigated these 684 
strains for susceptibility to colistin and for mcr-1 carriage. 
The strains from the 4 predominant serogroups (online 
Technical Appendix Table, http://wwwnc.cdc.gov/EID/
article/22/7/16-0234-Techapp1.pdf) can be considered 
representative of swine-pathogenic E. coli strains isolated 
from farm animals, but not food products, in Japan. MICs 
were determined by using the agar dilution method accord-
ing to the recommendations of the Clinical and Laboratory 
Standards Institute (6). The presence of mcr-1 was detected 
by PCR (3).
Among the 684 strains examined, colistin MICs exhib-
ited a bimodal distribution of 0.25–128 µg/mL and peaked 
at 0.5 and 16 µg/mL (online Technical Appendix Figure). 
According to the European Committee on Antimicrobial 
Susceptibility Testing criterion (7), in which isolates with 
an MIC of >4 µg/mL are considered colistin resistant, 309 
(45%) of the 684 strains were classified as colistin resis-
tant. The gene mcr-1 was detected in 90 (13%) strains, and 
the MICs for these mcr-1–positive strains ranged from 8 
to 128 µg/mL (online Technical Appendix Figure). Among 
the 309 colistin-resistant strains, mcr-1–positive and mcr-
1–negative isolates had the same 50% and 90% MICs, 16 
and 32 µg/mL, respectively. These results indicate that a 
high proportion of swine-pathogenic E. coli in Japan are 
resistant to colistin, that mcr-1 has already been widely dis-
seminated among these strains, and that the level of colistin 
resistance mediated by mcr-1 is similar to that mediated by 
mcr-1–independent mechanisms.
In 2004, colistin-resistant E. coli already represented 
77% of the isolates, and the positivity rates varied from 
year to year (26%–82%) (Figure). First detection of mcr-
1–positive strains was in 2007, and the proportion of mcr-1 
positivity has risen, especially since 2009 (Figure). During 
2013–2014, approximately half of the strains isolated were 
mcr-1 positive (Figure), and most colistin-resistant strains 
isolated during these 2 years carried mcr-1 (85% and 62% 
in 2013 and 2014, respectively). Of note, the rates of mcr-
1–positive strains among the 4 serogroups isolated from 
2010 through 2014 did not differ significantly (χ2 test): 22 
(20%) of 110 in O139, 38 (38%) of 100 in O149, 19 (26%) 
of 73 in O116, and 6 (32%) of 19 in OSB9. This finding 
suggests that the sharp rise in the proportion of mcr-1–posi-
tive strains has been driven by plasmid-mediated horizontal 
gene transfer, not by the expansion of a specific clone. 
In Japan, rates of isolation of colistin-resistant and 
mcr-1–positive E. coli strains from healthy animals are low, 
1.00% and 0.02% of 9,308 strains examined, respectively 
(4). These low rates may be the result of the prudent use 
of colistin in Japan. During 2000–2007 in Japan, colistin 
use in swine did not increase significantly (8). However, 
our data show that mcr-1 has recently been disseminated 
among swine-pathogenic E. coli in Japan, which might be 
associated with the use of colistin to treat disease in swine. 
Although mcr-1–positive bacteria have not yet been isolat-
ed from humans in Japan (4), the sharp increase in swine-
pathogenic E. coli in animal strains implies a risk for trans-
mission of mcr-1 from these strains to human-pathogenic 
bacteria, a serious concern for human medicine. More ac-
tive surveillance of mcr-1–positive colistin-resistant bacte-
ria in human and animal environments is needed.
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To the Editor: Yellow fever is disease caused by a 
flavivirus that is transmitted to humans and nonhuman pri-
mates through the bites of infected mosquitoes. In 2013, 
an estimated 130,000 persons in Africa experienced fever 
with jaundice or hemorrhage associated with yellow fever; 
≈78,000 of these infections were fatal (1).
Recently, an outbreak of yellow fever was reported in 
Angola (2). This serious viral disease affects persons liv-
ing in and visiting tropical regions of Africa and Central 
and South America (3). No case of yellow fever had been 
confirmed in China until this year (3). With the increased 
population movement between Africa and China, the risk 
for yellow fever in China is increasing.
In March 2016, a 34-year-old man who had recently 
returned to China from Angola sought medical treatment 
at the Shanghai Public Health Clinical Center in Shanghai, 
China. He reported a 4-day history of malaise, myalgia, 
weakness, nausea, vomiting, and fever reaching 38.8°C. 
The patient had been treated with several antimicrobial 
drugs when he was in Angola, but symptoms did not re-
solve. He had no history of immunodeficiency or immune-
inhibitory drug use. No endocrine, metabolic, or autoim-
mune abnormalities were found.
Nine years earlier, the patient had undergone cardiac 
valve replacement for rheumatoid heart disease and was 
currently receiving warfarin therapy. Because his treating 
physicians were concerned about the potential effect of yel-
low fever vaccine on the patient’s international normalized 
ratio (ratio of reference to measured prothrombin times), 
the patient traveled to Africa for work without receiving 
vaccination for yellow fever.
Physical examination revealed a temperature of 37°C. 
Neither rash nor jaundice were evident. Blood examination 
revealed a low leukocyte count (1.66 × 109 cells/L [refer-
ence range 3.50–9.50 × 109 cells/L]), a low absolute lym-
phocyte count (0.92 × 109 cells/L [1.1–3.2 × 109 cells/L), a 
normal erythrocyte count (4.60 × 1012 cells/L [4.30–5.80 × 
1012 cells/L]), and a low platelet count (43 × 109 platelets/L 
[125–350 × 109 platelets/L). The patient had low levels 
of circulating CD3+ cells (540/mL [690–2,540/mL) and 
CD8+ cells (97/mL [190–1,140/mL]) and normal levels of 
CD4+ T-cells.
C-reactive protein level was 4.31 mg/L (reference 
range 0–3.0 mg/L), lactate dehydrogenase was 1,086 
U/L (109–245 U/L), alanine aminotransferase was 882 
U/L (7–40 U/L), total bilirubin was 13.5 µmol/L (0–17 
µmol/L), and direct bilirubin was 7.4 µmol/L (0–5.4 
µmol/L). The patient had normal levels of thyroid-stim-
ulating hormone, and no DNA, nuclear, or thyroglobulin 
antibodies were detected.
Test results for HIV, malaria, and dengue virus infec-
tion were negative. Serum and urine samples were posi-
tive for yellow fever virus and negative for dengue and 
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